<DOC>
	<DOCNO>NCT00363909</DOCNO>
	<brief_summary>RATIONALE : Citalopram may help relieve hot flash woman breast cancer . It yet know dose citalopram effective treat hot flash postmenopausal woman . PURPOSE : This randomized phase III trial study three different dos citalopram compare well work treat postmenopausal woman hot flash .</brief_summary>
	<brief_title>Citalopram Treating Postmenopausal Women With Hot Flashes</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate efficacy three different dos citalopram hydrobromide hot flash score postmenopausal woman history breast cancer postmenopausal woman wish take estrogen replacement therapy fear increase risk breast cancer . Secondary - Compare side effect profile regimens patient . - Compare effect regimens secondary outcome mood interference activity hot flash . - Determine CYP2C19 CYP2D6 polymorphisms predict efficacy various dos citalopram hydrobromide . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord age ( 18-49 year vs ≥ 50 year ) , tamoxifen ( yes v ) , selective estrogen-receptor modulators ( SERMs ) ( yes v ) , aromatase inhibitor ( yes v ) , duration hot flash ( &lt; 9 month vs ≥ 9 month ) , frequency hot flash per day ( &lt; 4 vs 4-9 v ≥ 10 ) . Patients randomize 1 4 treatment arm . - Arm I ( low-dose citalopram hydrobromide ) : Patients receive 1 tablet oral citalopram daily week 2-7 . - Arm II ( medium-dose citalopram hydrobromide ) : Patients receive 1 tablet oral citalopram daily week 2 2 tablet daily week 3-7 . - Arm III ( high-dose citalopram hydrobromide ) : Patients receive 1 tablet oral citalopram daily week 2 , 2 tablet daily week 3 , 3 tablet daily week 4-7 . - Arm IV ( placebo ) : Patients receive 1-3 placebo tablet daily week 2-7 . All patient complete diary hot flash incidence week 1-7 undergo blood collection periodically study treatment translational research study . A Symptom Experience diary complete weekly Profile Mood States Hot Flash-Related Interference Scale questionnaire complete baseline week 7 .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Must meet 1 follow criterion : History breast cancer No current malignant disease No history breast cancer refuse estrogen replacement therapy due perceive increased risk breast cancer Bothersome hot flash , define hot flash ≥ 14 times/week sufficient severity make patient desire therapeutic intervention Presence hot flash ≥ 1 month prior study entry Hormone receptor status specify PATIENT CHARACTERISTICS : Female Postmenopausal , define 1 follow criterion : Absence menstrual period past 12 month Bilateral oophorectomy Absence menstrual period past 6 month folliclestimulating hormone ( FSH ) level &gt; 40 mIU/mL ECOG performance status 01 Life expectancy ≥ 6 month Willing provide blood sample study participation No history allergic adverse reaction citalopram hydrobromide selective serotonin reuptake inhibitor ( SSRIs ) No document mania hypomania PRIOR CONCURRENT THERAPY : At least 4 week since prior concurrent antineoplastic chemotherapy At least 4 week since prior concurrent androgen , estrogen , progestational agent At least 3 month since prior antidepressant use , include Hypericum perforatum ( St. John 's wort ) Concurrent tamoxifen , raloxifene , aromatase inhibitor allow constant dose ≥ 4 week continue medication study period No concurrent plan agent treat hot flash ( e.g. , phenobarbital , megestrol , clonidine ) Stable dose vitamin E allow long start &gt; 30 day prior study entry Concurrent soy allow Concurrent gabapentin allow reason hot flash constant dose ≥ 1 month continue study period</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>psychosocial effect cancer treatment</keyword>
	<keyword>hot flash</keyword>
	<keyword>breast cancer</keyword>
</DOC>